Tips to elicit your patient’s family history of BRCA1 and BRCA2

20th October 2021

Taking a good family history allows geneticists to triage referrals appropriately.

BRCA1 and BRCA2 gene mutations are characterised by an increased risk of breast and ovarian cancers; furthermore, the genes also carry an increased risk of prostate cancer (Mehrgou et al, 2016). In some populations (such as the Ashkenazi Jewish community) there is a higher incidence of BRCA1 and 2, therefore a lower threshold for referral should be considered.

Taking a concise detailed family history is an important part of the consultation. Patients with a strong family history should be referred to a clinical geneticist for further assessment.

The referral letter should include all relevant information, including:

  • First and second degree affected
  • Age at diagnosis
  • Tumour type
  • Stage of the disease
  • Survival rate

For more tips, access GatewayC’s ‘Ovarian Cancer – Early Diagnosis’ course which features Dr Emma Woodward, Consultant Clinical Geneticist, discussing the link between family history and ovarian cancer.

Find out more:

  • Access GatewayC’s ‘Ovarian Cancer – Early Diagnosis’ course here
  • Read Genomics Education Programme (2021) ‘Taking and drawing a family history’ here
  • Read Mehrgou, A. and Akouchekian, M. (2016) ‘The importance of BRCA 1 and BRCA 2 genes mutations in breast cancer development’ here
  • Read Target Ovarian Cancer (2019) ‘Familial ovarian cancer: a guide for primary care’ here
  • Read GatewayC’s ‘How reliable is the CA125?’ here

LinkedIn | Twitter | Facebook

Latest from the Blog

New-onset diabetes and pancreatic cancer

New-onset diabetes and pancreatic cancer

18th November 2021 Potential pitfall: Diabetes, especially Type 2, is common among the general population. However, unexplained new-onset diabetes should be investigated as a possible indicator of pancreatic cancer. It is also important to ask patients about other...

read more
Myeloma and C.R.A.B

Myeloma and C.R.A.B

30th September 2021 C.R.A.B is the acronym designed to simplify the most typical clinical manifestations of multiple myeloma. Clinicians should consider the following indicators in a potential myelomadiagnosis: C: Calcium – hypercalcaemia Symptoms include: excessive...

read more

Related Posts

New-onset diabetes and pancreatic cancer

New-onset diabetes and pancreatic cancer

18th November 2021 Potential pitfall: Diabetes, especially Type 2, is common among the general population. However, unexplained new-onset diabetes should be investigated as a possible indicator of pancreatic cancer. It is also important to ask patients about other...

read more
Myeloma and C.R.A.B

Myeloma and C.R.A.B

30th September 2021 C.R.A.B is the acronym designed to simplify the most typical clinical manifestations of multiple myeloma. Clinicians should consider the following indicators in a potential myelomadiagnosis: C: Calcium – hypercalcaemia Symptoms include: excessive...

read more